Research Letter

Role of Weight Loss Induced Prediabetes Remission in the Prevention of Type 2 Diabetes – Time to Improve Diabetes Prevention

Reiner Jumpertz von Schwartzenberg[1,2,3*], Elsa Vazquez Arreola[4*], Arvid Sandforth[1,2,3], Robert L. Hanson[4], Andreas L. Birkenfeld[1,2,3,5]

[1]German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, 85764, Neuherberg, Germany
[2]Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany
[3]Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany
[4]Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, 85014 Phoenix, AZ, USA
[5]Department of Diabetes, Life Sciences & Medicine Cardiovascular Medicine & Sciences, Kings College London, UK

*contributed equally

Corresponding Author:
Prof. Dr. med. Andreas Birkenfeld, M.D.
Internal Medicine IV, Department of Diabetology, Endocrinology and Nephrology,
Eberhard-Karls University Tübingen
Otfried-Müller-Str. 10
72076 Tübingen
Germany
andreas.birkenfeld@med.uni-tuebingen.de

Abstract

Aims/hypothesis: For individuals with prediabetes, the current American Diabetes Association (ADA) guidelines recommend a body weight loss >7% to prevent the development of type 2 diabetes (T2D) without any glycemic target goals. However, we have recently shown that weight loss induced prediabetes remission reduces relative T2D risk by 73% within the following two years. Therefore, we investigated relative T2D risk reduction in people with weight loss vs those with weight loss and prediabetes remission in an independent cohort: the randomized controlled Diabetes Prevention Program (DPP).

Methods: Individuals who lost >7% of their body weight over the first year were included in this analysis. Of these, 416 were assigned to intensive lifestyle intervention and 64 received placebo. Remission of prediabetes was defined by normalization of fasting and 2h glucose during an oral glucose tolerance test and a normalized HbA1c according to ADA criteria. Non-remission was given when at least one of these criteria was not met. We computed Kaplan-Meier curves and compared them using log-rank tests and future T2D risk was assessed by computing the relative risk between groups.

Results: In DPP, 480 individuals achieved a weight loss of >7% and of these 114 additionally achieved prediabetes remission. Over the period of 6 years, those who achieved weight loss and remission had a 66% lower relative risk to develop T2D compared to those who only met the 7% weight loss goal [RR=0.34, 95% CI (0.15, 0.76)]. Similarly, weight loss responders had a lower relative future T2D risk compared to weight loss non-responders [RR=0.28, 95% CI (0.13, 0.64)]. Importantly, there was not a single T2D case in weight loss responders for up to 4 years after the intervention.

Conclusions/interpretation: The combination of achieving weight loss goals and prediabetes remission is most effective in reducing future T2D risk. Thus, beside weight loss goals, interventions in individuals with prediabetes should be continued until prediabetes remission is achieved and this ought to be adapted in current clinical praxis guidelines.

Research Letter

By 2050, more than 1.3 billion people worldwide are expected to have diabetes; the vast majority of patients will have type 2 diabetes (T2D) [1]. T2D increases the risks of many chronic diseases, including micro- and macrovascular diseases, neurodegenerative disease, and cancer, posing a huge burden on affected people and societies. T2D has unequal impacts, with fewer than 10% of people affected in low and middle-income countries receiving proper care [1]. Prevention of T2D is an urgent clinical need.

Prediabetes is the strongest risk factor for the development of T2D and also predisposes to other diseases than diabetes, particularly cancer, microvascular disease, and cardiovascular disease [2,3]. We have recently shown in a predefined post hoc analysis from the Prediabetes Lifestyle Intervention Study (PLIS) [4] as well as the US Diabetes Prevention Program (DPP) [4-6] that lifestyle intervention induced weight loss of > 5 % (including dietary counseling and increased physical exercise) led to remission of prediabetes in 73% of patients [4]. Remission rates increased with increasing weight loss. Prediabetes remission was defined as return to normal fasting glucose (<5·6 mmol/l), normal glucose tolerance (2-h post-load glucose <7·8 mmol/l) and HbA1c levels below 39 mmol/mol at the end of the lifestyle intervention. Importantly, weight loss induced prediabetes remission in PLIS not only reduced the relative risk of developing T2D, it was also associated with lower renal albumin excretion and higher skin small vessel density as assessed by raster-scanning optoacoustic mesoscopy (RSOM) [4], suggesting improved small vessel integrity.

Interestingly, mechanisms driving weight loss induced prediabetes remission seem to differ from those leading to remission of T2D. In T2D, elegant studies in the DIRECT trial showed that the difference between people with diabetes going into remission and those not going into remission was the ability of beta-cells to respond to weight loss with an improvement in function and insulin secretion [7,8]. Mechanistically, it was suggested that lower hepatic VLDL palmitate secretion contributed to the recovery of beta-cells in persons going into remission compared to those not going into remission [8,9]. Importantly, insulin sensitivity did not contribute to the effect and was not different between persons with T2D reaching remission and those who did not [7]. In contrast, in our study, weight-loss induced remission of prediabetes to normal glucose regulation was driven by an improvement in insulin sensitivity which was independent of differences in weight loss. Mechanistically, persons with prediabetes going into remission to normal glucose regulation lost more visceral adipose tissue (VAT) mass, which likely contributed to the observed improvement in insulin sensitivity [4].

We believe that these seemingly discordant mechanisms can be well explained by the natural history of T2D. Whereas the transition from normal glucose regulation to impaired glucose tolerance is primarily mediated by insulin resistance, the transition from impaired glucose tolerance to T2D is additionally mediated by beta-cell failure [10]. Thus, in reverse, it seems plausible that remission from T2D to a non-diabetic state is driven by recovery of beta-cell function, whereas remission from prediabetes to normal glucose regulation is driven by

improvement in insulin resistance. This further implies that remission of prediabetes targets a timepoint when beta cells are not yet clinically relevantly and permanently damaged. Remission of prediabetes is, therefore, a window of opportunity to protect beta-cell function in the long term.

Current American Diabetes Association (ADA) guidelines on the prevention of diabetes state that persons with prediabetes should lose body weight of 7% or more without setting glucose related target values [11]. We suggest that body weight loss and glycemic remission goals should be considered together, since weight loss and remission of prediabetes together offer the most efficient protection against the development of incident T2D. To support this notion, we compared incident T2D over 4 and 6 years in all persons in US-Diabetes Prevention Program ClinicalTrials.gov, registration no. NCT00004992) with prediabetes who reached the guideline goal of at least 7% weight loss during the lifestyle intervention to those who lost at least 7% of body weight and additionally reached normal glucose regulation as defined above. This secondary analysis included 480 participants randomized to the intensive lifestyle intervention (ILS) or placebo, that lost at least 7% of their baseline weight by year 1, had complete measurements of HbA1c, FPG, and 2hr-PG at baseline and year 1, and had follow-up data on diabetes diagnosis; participants assigned to metformin were not included.

In DPP, there were 480 participants who lost at least 7% of body weight from baseline to year 1 and who had follow-up data on diabetes diagnosis. Of them 114 were responders (they remitted back to normal glucose regulation at year 1). Of the 480 people who lost >=7% of weight by year 1, 43 were diagnosed with diabetes by year 4 of follow-up. Of the 114 responders who lost >=7% of weight and went into remission to normal glucose regulation by year 1, only one was diagnosed with diabetes by year 4 of follow-up as illustrated in the figure below.

We grouped the 480 people who lost>=7% of weight in Group 1, and the 114 responders who lost >=7% of weight in Group 2. The participants in Group 1 had a significantly lower relative risk of progression to diabetes compared to Group 2 [RR=0.34, 95% CI (0.15, 0.76)]. The Fischer's exact test indicated that the proportion of progressors to diabetes in Group 1 was significantly different from the proportion of progressors to diabetes in Group 2 (p=0.002).

Below, we show the Kaplan Meier curve for survival probability without diabetes for participants in Group 1 and Group 2. It can be observed that after year 2, participants in

Group 1 started to have lower probability for diabetes development than participants in Group 2 (p=0.006).

Moreover, we compared non-responders to responders among participants who lost >7% of body weight in DPP. From the 480 DPP participants who lost at least 7% of weight from baseline to year 1, 114 were responders (they remitted to normal glucose regulation at year 1) and 366 were non-responders (they did not remit to normal glucose regulation at year 1). Of the 366 non-responders, 42 were diagnosed with diabetes by year 4 of follow-up. Of the 114 responders, one was diagnosed with diabetes by year 4 of follow-up. Responders had a significantly lower relative risk of progression to diabetes compared to non-responders over the period of 6 years [RR=0.28, 95% CI (0.13, 0.64)]. The proportion of progressors to diabetes in responders was significantly different from the proportion of progressors to diabetes in non-responders (p=0.0002).

Below, we show the Kaplan Meier curve for survival probability for responders and non-responders. It can be observed that after year 2, responders started to have a lower probability for diabetes development than non-responders (p=0.001).

In summary, combining the most recent guideline recommendation for people with prediabetes to lose   7% of body weight [11] with remission from prediabetes to normal glucose regulation, reduces the relative risk to develop T2D by 66% within 6 years and importantly within the first 4 years, the was only one single diabetes case in this group, indicating that less than 1% of these patients develop diabetes after 4 years. As weight loss is a determining factor for the remission of prediabetes [6], our findings indicate that individuals with prediabetes who did not achieve remission (non-responders) after losing ≥7% of their body weight should continue to lose weight until they reach their personal threshold [12,13] . The combination of weight loss and prediabetes remission gives patients and doctors a measurable and reliable goal for their efforts.

We conclude that remission of prediabetes to normal glucose regulation is a crucial therapeutic strategy to reduce the huge burden of T2D in the future. The concept of remission of prediabetes needs to be considered for future guidelines, since it has the potential to protect beta-cell function before the development of T2D and to potentially reduce the rising incidence and prevalence of T2D worldwide.

Acknowledgements:

ALB, RJvS, AS are grateful to the support by the German Federal Ministry for Education and Research (01GI0925) via the German Center for Diabetes Research (DZD e.V.); Ministry of Science, Research and the Arts Baden-Württemberg and Helmholtz Munich.

The Diabetes Prevention Program (DPP) was conducted by the DPP Research Group and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the General Clinical Research Center Program, the National Institute of Child Health and Human Development (NICHD), the National Institute of Aging (NIA), the Office of Research on Women's Health, the Office of Research and Minority Health, the Centers for Disease Control and Prevention (CDC), and the American Diabetes Association. The data (and samples) from the DPP were supplied by the NIDDK Central Repository. This manuscript was not prepared under the auspices of the DPP and does not represent analyses or conclusion of the DPP Research Group, the NIDDK Central Repository, or the NIH.

Funding

The analysis for this paper was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). DPP was supported by NIDDK and other agencies. German Federal Ministry for Education and Research (01GI0925) via the German Center for Diabetes Research (DZD e.V.); Ministry of Science, Research and the Arts Baden-Württemberg; Helmholtz Munich. ALB was supported by a research grant from the German Research Foundation (GRK2816; BI 1292/9-1; BI 1292/10-1; BI1292/ 12-1). RJvS was funded by Helmholtz Munich and the Helmholtz Association via a Helmholtz Young Investigator Group (VH-NG-1619) and by the Cluster of Excellence (EXC-2124/1-03.007).

The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Authors' relationships and activities

ALB received lecture / advisory board fees from Bayer; lecture fees from NovoNordisk, Boehringer Ingelheim, Daiichi Sankyo, Lilly paid to University Hospital Tübingen: ALB is co-founder of Eternygen GmbH

Contribution statement

ALB is the guarantor for the work and conceptualized the details of this analysis. RJvS, EVA, AS and RLH accessed and analyzed the data. ALB wrote the manuscript; RJvS, EVA, RLH and AS edited the manuscript.

References

1. Collaborators, G.B.D.D. (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 402, 203-234. 10.1016/S0140-6736(23)01301-6

2. Stefan, N. and Schulze, M.B. (2023) Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. *The lancet. Diabetes & endocrinology* 11, 426-440. 10.1016/S2213-8587(23)00086-4

3. Hanefeld, M. *et al.* (2016) The metabolic vascular syndrome - guide to an individualized treatment. *Reviews in endocrine & metabolic disorders*. 10.1007/s11154-016-9345-4

4. Sandforth, A. *et al.* (2023) Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). *The lancet. Diabetes & endocrinology* 11, 798-810. 10.1016/S2213-8587(23)00235-8

5. Diabetes Prevention Program Research, G. (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. *The lancet. Diabetes & endocrinology* 3, 866-875. 10.1016/S2213-8587(15)00291-0

6. Fritsche, A. *et al.* (2021) Different Effects of Lifestyle Intervention in High- and Low-Risk Prediabetes: Results of the Randomized Controlled Prediabetes Lifestyle Intervention Study (PLIS). *Diabetes* 70, 2785-2795. 10.2337/db21-0526

7. Zhyzhneuskaya, S.V. *et al.* (2020) Time Course of Normalization of Functional beta-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. *Diabetes care* 43, 813-820. 10.2337/dc19-0371

8. Al-Mrabeh, A. *et al.* (2020) Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. *Cell metabolism* 31, 233-249 e234. 10.1016/j.cmet.2019.11.018

9. Rothberg, A. *et al.* (2024) Remission of type 2 diabetes: always more questions, but enough answers for action. *Diabetologia*. 10.1007/s00125-023-06069-1

10. Tabak, A.G. *et al.* (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *Lancet* 373, 2215-2221. 10.1016/S0140-6736(09)60619-X

11. American Diabetes Association Professional Practice, C. (2024) 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024. *Diabetes care* 47, S43-S51. 10.2337/dc24-S003

12. Taylor, R. *et al.* (2023) Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis. *Clin Sci (Lond)* 137, 1333-1346. 10.1042/CS20230586

13. Taylor, R. (2021) Type 2 diabetes and remission: practical management guided by pathophysiology. *J Intern Med* 289, 754-770. 10.1111/joim.13214